ABUS - Arbutus Biopharma Corporation
NEXT EARNINGS:
Mar 26, 2026
(in 29 days)
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.50
DETAILS
HIGH:
$8.50
LOW:
$8.50
MEDIAN:
$8.50
CONSENSUS:
$8.50
UPSIDE:
90.58%
Market Cap:
857.77M
Volume:
1,223,530
Avg Volume:
1,521,958
52 Week Range:
2.71-5.1
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.72
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
44
IPO Date:
2007-07-26
EPS (TTM):
-0.38
P/E Ratio:
-8.68
Revenue (TTM):
6.17M
Total Assets:
131.71M
Total Debt:
1.29M
Cash & Equiv:
36.33M
Rev Growth (5Y):
0.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-60.1%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-13 | $-0.04 | $-0.06 | +28.6% | $529000 | $841000 | -37.1% |
| 2025-08-06 | $0.01 | $-0.02 | +150.0% | $10.7M | $1.6M | +575.0% |
| 2025-05-14 | $-0.13 | $-0.09 | -44.4% | $1.8M | $2.2M | -21.3% |
| 2025-03-27 | $-0.07 | $-0.08 | +12.5% | $1.6M | $2.3M | -30.3% |
| 2024-11-06 | $-0.10 | $-0.10 | 0.0% | $1.3M | $1.6M | -15.3% |
| 2024-08-01 | $-0.11 | $-0.10 | -10.0% | $1.7M | $1.9M | -6.7% |
| 2024-05-02 | $-0.10 | $-0.10 | 0.0% | $1.5M | $2.1M | -28.7% |
| 2024-02-29 | $-0.12 | $-0.12 | 0.0% | $2.1M | $4.8M | -55.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.17M | 18.14M | 39.02M | 10.99M | 6.91M | 6.01M | 5.90M | 10.70M | 1.50M | 24.87M | 15.00M | 15.46M |
| Net Income | (69.92M) | (72.85M) | (69.46M) | (76.25M) | (63.74M) | (153.72M) | (57.10M) | (84.40M) | (384.10M) | (61.12M) | (38.80M) | (14.06M) |
| EPS | -0.38 | -0.44 | -0.46 | -0.73 | -0.86 | -2.69 | -1.03 | -1.54 | -7.24 | -1.34 | -1.80 | -0.92 |
| Total Assets | 131.71M | 144.40M | 195.42M | 204.49M | 137.08M | 105.53M | 227.91M | 237.20M | 275.90M | 712.29M | 118.20M | 71.72M |
| Total Debt | 1.29M | 8.72M | 12.55M | 18.91M | 22.54M | 3.36M | 0 | 12.00M | 12.00M | 0 | 0 | 0 |
| Cash & Equivalents | 36.33M | 26.29M | 30.78M | 109.28M | 52.25M | 31.80M | 36.94M | 54.30M | 23.40M | 166.78M | 72.20M | 68.72M |
| Operating Cash Flow | (64.85M) | (85.94M) | (35.36M) | (67.53M) | (51.44M) | (71.01M) | (67.90M) | (48.60M) | (57.88M) | (54.78M) | (12.42M) | (6.74M) |
| Free Cash Flow | (65.03M) | (86.94M) | (35.87M) | (68.34M) | (51.67M) | (71.59M) | (69.04M) | (55.86M) | (61.88M) | (57.07M) | (13.48M) | (7.46M) |
| FCF per Share | -0.35 | -0.52 | -0.24 | -0.64 | -0.68 | -1.25 | -1.25 | -1.02 | -1.17 | -1.26 | -0.62 | -0.49 |
| Book Value | 97.37M | 106.02M | 136.85M | 169.44M | 101.97M | 72.74M | 200.23M | 182.50M | 203.00M | 547.68M | 88.00M | 59.19M |
| Cash & ST Investments | 122.62M | 126.00M | 146.91M | 155.32M | 123.27M | 90.83M | 124.62M | 126.40M | 130.50M | 181.30M | 112.20M | 68.72M |
| ROC Equity | -0.72 | -0.69 | -0.51 | -0.45 | -0.63 | -2.11 | -0.29 | -0.46 | -1.89 | -0.11 | -0.44 | -0.24 |